Showing 5061-5070 of 8848 results for "".
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- TOGETHER-PsO: Combination Therapy Links Obesity Treatment to Psoriasis Clearancehttps://practicaldermatology.com/news/together-pso-trial-links-obesity-treatment-to-enhanced-psoriasis-clearance/2485716/New data show that a combination therapy of ixekizumab (Taltz) plus tirzepatide (Zepbound) was superior to ixekizumab alone for achieving PASI 100 and ≥10% weight loss at 36 weeks in adults with moderate-to-severe plaque psoriasis. The phase 3b TOGETHER-PsO
- Commentary: Is the IMQ Mouse Model Hindering Psoriasis Research?https://practicaldermatology.com/news/commentary-is-the-imq-mouse-model-hindering-psoriasis-research/2485698/A perspective piece in the Journal of Investigative Dermatology takes a criticial look at the imiquimod (IMQ) mouse model, suggesting its unversality and commonality may be impeding translational progress in psoriasis resea
- Analysis: Agent Orange Exposure Linked to Acral Melanoma Risk in US Veteranshttps://practicaldermatology.com/news/analysis-agent-orange-exposure-linked-to-acral-melanoma-risk-in-us-veterans/2485639/Acral melanoma (AM), a rare melanoma subtype, showed risk factor patterns in a large Veterans Affairs (VA)–based analysis spanning more than two decades, according to new data. In this case-control study of US veterans from 20
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp